Advanced Filters
noise

pulmonary-arterial-hypertension Clinical Trials

A listing of pulmonary-arterial-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 82 clinical trials

Dapagliflozin in Pulmonary Arterial Hypertension

The purpose of this study is to investigate the effects of dapagliflozin on exercise capacity and hemodynamics in patients with pulmonary arterial hypertension

18 - 100 years of age Both Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Spironolactone for Pulmonary Arterial Hypertension

Background High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as inflammation, leading to worsening of the disease. A …

18 - 100 years of age Both Phase 2

Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)

The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

18 - 100 years of age Both Phase N/A
O Olivia Vayer

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.

18 - 100 years of age Both Phase N/A
K Kelly Burke, RN

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk distance (6MWD) and HRQOL improvement that often exceeds the effect …

18 - 100 years of age Both Phase N/A
F Fabio Dardi, MD, PhD

COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNgina

The prevalence of critical ab extrinsic compression of left main coronary artery (LMCA) is very high in patients with pulmonary arterial hypertension (PAH) symptomatic for angina (up to 40% according to a recent study of 121 patients with PAH). The element that most of all correlates with the degree of …

18 - 100 years of age Both Phase N/A
F Francis COUTURAUD, Pr

Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension is characterized by a progressive increase in pulmonary vascular resistance inducing shortness of breath and exercise intolerance. We aim to correlate cardiac function (evaluated at rest by right heart catheterism and RMN) to exercise capacity (evaluated by endurance time at 75% of maximal workout), in prevalent patients …

18 - 100 years of age Both Phase N/A
F Fredrik Frick

Effect of CS1 in Subjects With Pulmonary Arterial Hypertension

This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other hemodynamic parameters. Elegible subjects will have a RHC to implant …

18 - 80 years of age Both Phase 2

Empagliflozin in Pulmonary Arterial Hypertension

The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial hypertension.

18 - 100 years of age Both Phase 2

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional symptoms in patients with pulmonary arterial hypertension (PAH).

18 - 80 years of age Both Phase 2

Rewrite in simple language using AI